Strategy/
Where does Dupixent fit into the treatment pathway?
Dupi is placed as the first line advanced therapy;
For patients inadequately controlled on TCS, and are candidates for systemic therapies
What are 3 main objectives of the STEM project?
Provide an anonymous vehicle to feed back on how well we are achieving our strategy
What areas can we improve across marketing sales and medical
Quantify element which elements work best, what areas can we make incremental small changes to improve
Spell correctly the generic name of all current and future competitors
Lebrikizumab
Nemolizumab
Tralokinumab
Baricitinib
Upadacitinib
Abrocitinib
Which is the only mammal that can’t jump?
Elephant
How many bones does an adult human have?
206
What are Dupixent’s main sources of growth?
Patients in the cycle of episodic management
Dupi as first line advanced therapy
Increase long term persistence on Dupi
(start and stay on therapy)
What are the 3 differentiating advantages we need to focus on at every call?
Sustained control long term (long term efficacy
Safe for long term use
Ease of use
Name the 4 Customer Segments
Trailblazer, Cautioner, Simplifier, Traditionalist
What is the longest river in the world?
Nile
How many sides, in total, would three triangles and three rectangles have?
21
What are the KSM’s for Dupixent?
Pt Identification – inadequately controlled severe AD
Type 2 – AD is a T2 disease requiring targeted approach and not immunosuppressant
Efficacy – sustained response with itch improving from 1st dose and up to 52 weeks
Safety – favourable safety data up to 3 years. >230,000 pts
Ease of use – Convenient application, no screening and monitoring, or drug -drug interactions
What support programs or service offerings do we have for HCPs
•Online (HCP website)
•Atopic Dermatitis Revealed (patient website)
•MyWaySupport PSP (reactive discussion)
•Dial an MSL Service
What is one key characteristic of each segment
T – keen to adopt new therapies
C- will not compromise on safety
S- Prioritises convenience and simplicity, treats episodically
T- Safety conscious, late adopter, uses conventional therapies, reserves D for most severe
Which nail on the finger grows the fastest? For a bonus 50 points also which is the slowest
Middle Finger Among the 5 fingernail (hand): The fastest growing nail is the one on our middle finger and the slowest growing nail is our thumb nail.
The rate of growth of our finger nails are related to the length of the terminal phalanges.
What did A.E. Frick invent in 1887, which are now worn by thousands if not millions of people?
Contact lenses
3 Strategic Imperatives or key areas of focus
With additional details for double points
Champion Type 2 science
Lead the market
Reimagine the stakeholder experience
Paed PBAC recommendations what can/can't we communicate?
PBAC recommendation received for <12year
Halo Effect: Shows safety in paeds through to adults
Continuous long term treatment from children through to adults not available for JAKs.
Do not know time frame as it is a process without specified timings so cannot suggest it is soon.
PBAC <12 years but TGA indication is 6-11 so indication does not match potential PBS so it is off label to speak about so needs to be dealt with
What is the priority messaging for each segment?
Trailblazer – Efficacious continuous control
Cautioner – Established Safety profile
Simplifier – Convenience and Efficacy
Traditionalist – beyond the most severe
What's the smallest country in the world?
Vatican City
Who is regarded as the best-selling female artist of all times by the Guinness World Records
Madonna
What topics of discussion are best managed through collaboration with your MSL
What are 5 the KSM’s for Dupixent
Pt Identification – inadequately controlled severe AD
Type 2 – AD is a T2 disease requiring targeted approach and not immunosuppressant
Efficacy – sustained response with itch improving from 1st dose
Safety – favourable safety data up to 3 years. >230,000 pts
Ease of use – Convenient application, no screening and monitoring, or D2D interactions
Describe Dupixent's target patients
Patients inadequately controlled after 1 month of TCS/TCI - EASI >20, PGA4 (severe) who would be considered for a systemic treatment. Profile aligned to PBS criteria
Patients who are inadequately controlled on systemics for switch to Dupixent (eg, breakthrough in cyclosporine)
JAK failure- efficacy or side effects
Adolescents 12-18 years with severe AD
Adults with Severe AD
Name all the colours in the rainbow in order
Red, orange, yellow, green, blue, indigo, violet
Which is the only edible food that never goes bad?
Honey